Trials / Completed
CompletedNCT04673266
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
Romiplostim for Prevention of Severe Chemotherapy Induced Thrombocytopenia in Lymphoma Patients - Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if the study drug, romiplostim, helps low platelet count caused by standard chemotherapy treatment for lymphoma. This study will also look at whether romiplostim can prevent the need for chemotherapy dose delays, chemotherapy dose reductions, and platelet transfusions. In addition, we will determine how safe it is to give romiplostim to people with lymphoma who have low platelet count from chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Romiplostim | All patients will begin weekly (+/- 2 days) romiplostim at 3 mcg/kg subcutaneously. The romiplostim dose will be titrated, based on weekly CBC/platelet counts. |
Timeline
- Start date
- 2020-12-14
- Primary completion
- 2026-04-07
- Completion
- 2026-04-07
- First posted
- 2020-12-17
- Last updated
- 2026-04-13
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04673266. Inclusion in this directory is not an endorsement.